Summary In a previous study, urologists, radiation oncologists and medical oncologists in Britain, Canada and the United States were asked to state how they would wish to be treated if they had urologic cancer as described in six clinical scenarios and whether they would agree to be entered in randomised clinical trials. This study disclosed major controversy regarding treatment options for each scenario and reluctance by these experts to enter randomised clinical trials. In the present study a second questionnaire which included a summary of the treatments selected initially was sent to the same 227 oncologists. Respondents were asked, in view of these additional information, how they would wish to be treated and whether they would enter themselves (or their patients) on randomised trials comparing the two treatment options most favoured by their colleagues. Most There is a large degree of controversy about the optimal management of patients with genitourinary malignancies. Despite this lack of consensus there has been only a small number of randomised clinical trials in urologic oncology that have addressed controversies regarding optimal treatment strategies (Raghaven et al., 1989) .
and the United States were asked to state how they would wish to be treated if they had urologic cancer as described in six clinical scenarios and whether they would agree to be entered in randomised clinical trials. This study disclosed major controversy regarding treatment options for each scenario and reluctance by these experts to enter randomised clinical trials. In the present study a second questionnaire which included a summary of the treatments selected initially was sent to the same 227 oncologists. Respondents were asked, in view of these additional information, how they would wish to be treated and whether they would enter themselves (or their patients) on randomised trials comparing the two treatment options most favoured by their colleagues. Most respondents did not modify their treatment preference. There was still poor agreement to enter themselves on trials (29%), but a higher proportion would offer such trials to their patients (45%). Thus the demonstration of controversy about optimum treatment did not influence personal bias, but could facilitate the entry of patients into trials that address major controversies. We conclude that treatment strategies of urologic oncologists are influenced minimally by opinions of their colleagues, but that the method of using surrogate questionnaires is a valuable aid to the design of clinical trials.
There is a large degree of controversy about the optimal management of patients with genitourinary malignancies. Despite this lack of consensus there has been only a small number of randomised clinical trials in urologic oncology that have addressed controversies regarding optimal treatment strategies (Raghaven et al., 1989) .
In an attempt to define controversies in the management of GU malignancies, and to establish whether current clinical trials in urologic oncology address important questions, we have surveyed previously 227 urologists, radiation oncologists and medical oncologists in Canada, Great Britain and the United States (Moore et al., 1988) . The population surveyed included one group of community based urologists, and the remainder were specialists known to practice urologic oncology on the basis of a publication about prostate or bladder cancer within the previous 3 years. The survey used the physician surrogate method initially developed for a study examining treatment preferences of physicians for different presentations of non-small cell lung cancer (Mackillop et al., 1986 (Mackillop et al., , 1987 The responses to the previous questionnaire were then summarised (presented in parenthesis in Table I ).
As shown in Table I , most of the treatments selected were similar to those chosen in the initial survey. The only change was an increase in preference for radiation therapy by British urologists and US medical oncologists. Over 95% of the physicians were aware that controversy existed about the management of localised prostatic cancer.
In the initial survey 31% of doctors stated they would agree to be randomised in a trial comparing radical prostatectomy to radiation therapy. After reviewing the evidence demonstrating the degree of controversy among their colleagues 29% stated they would agree to be randomised in such a trial. However, 58% of respondents stated that they would approach a patient in their practice about entry into this trial (P<10-1). The responses to the previous questionnaire were then summarised (presented in parenthesis in Table II) .
We did detect changes in treatment preferences in the follow up questionnaire (Table II) . This related to the use of chemotherapy either by itself or in combination with cystectomy and/or radiotherapy. Initially 28% of physicians selected chemotherapy as part of their treatment while in the follow-up study this had increased to 43% (P<0.008 The responses to the previous questionnaire were then summarised (see in parentheses in Table III) . Treatment selections changed marginally and preferences were distributed evenly among the four most popular options (Table III) . The proportion of specialists choosing no treatment was equal among physicians of different locations and specialities.
Respondents were then asked if they would agree to be randomised on a trial comparing human lymphoblastoid interferon alone to interferon plus vinblastine. Originally 48% had agreed to enter this trial. In the follow-up 53% of physicians agreed to be randomised and 60% stated they would enter their patients on such a trial. Among the 157 specialists who responded to our questionnaire none chose treatment with interferon or vinblastine for themselves.
The respondents were then asked if they would agree to be randomised in a hypothetical trial that compared the two options chosen most frequently by these experts in the original survey -nephrectomy (chosen by 29%) vs no treatment (chosen by 24%). Only 24% of physicians agreed to be randomised in such a trial while 37% stated they would offer this trial to their patients. Among doctors who had chosen either nephrectomy or no treatment for themselves agreement was 33%. (14) 44 (44) 0 (0) 0 (0) 0 (0) 9 (31) Other 11 (15) 12 (22) 6 (10) 16 (12) 11 (21) 3 (6) Treatment includes 43 (28) 16 (22) 22 (11) 56 (32) 79 (50) 38 (23) Our follow-up questionnaire sought to disclose some potential reasons for the poor support of these clinical trials. Possibilities might include (i) a lack of awareness that alternative forms of management were considered acceptable by colleagues, (ii) a wish to select one's own treatment on the The present survey demonstrated consistently a higher rate of agreement by physicians to enter their patients rather than themselves into randomised clinical trials (P< 10-6). Some respondents questioned the ethics of a doctor who would not agree to be randomised into a clinical trial that he would offer to one of his patients. We would agree with this statement in the context of a trial that included a treatment approach that was unconventional, dangerous or previously shown to be of no benefit. In their previous study of physicians treating lung cancer Mackillop et al. (1986) identified such situations. The trials presented in our questionnaire did not offer unconventional options. For example, the proposed trial comparing radical prostatectomy with radiation therapy for localised prostate cancer compares two treatments which are equally accepted amongst the expert community. Freedman (1987) has defined this state of genuine uncertainty amongst experts about the relative merits of treatments as 'equipoise'. It would appear reasonable for a physician to have an individual preference for one of these options. It also seems quite defensible that a physician might wish to follow his individual bias when selecting treatment for himself but to recognise that equipoise exists and to offer alternative strategies to his patients.
While specialists recognise that controversy exists they appear to have difficulty in accepting that their own opinions may not be based on scientific data. Many comments on the questionnaires supported this premise ('prostatectomy offers the best chance of cure', 'prostatectomy too toxic'. 'toxicity of radiation too great' etc.). This could reflect problems inherent in having modality oriented methods of training and practice when dealing with diseases whose optimal management may be multidisciplinary. Physicians-in-training and specialists may lack exposure to alternative points of view. Psychological research demonstrates that we tend to conform with the beliefs of our colleagues. In addition we more readily believe and recall information that supports our biases while disregarding evidence that conflicts with them (Aronson, 1972) .
It is remarkable that there was such good agreement (53%) by clinicians to be randomised into the trial of interferon with or without vinblastine if they had asymptomatic metastatic renal cell cancer. This occurred despite the fact that no physician chose either of these agents as their preferred treat-ment. In contrast, the trial comparing radical prostatectomy with radiation therapy for localised prostate cancer involved the two treatment options selected by 90% of respondents but only 29% agreed to participate. These findings suggest that some trials which are successful in accruing patients may be lacking in clinical relevance. This situation may have developed from an awareness that clinical trials which address controversial issues are difficult to carry out. Clinical relevance is then sacrificed for the sake of feasibility in a setting where clinical investigation is seen as a desirable activity. A clinical trial that seeks to answer a clinically irrelevant question, even if of exquisite methodology, is at best a waste of resources that could be employed elsewhere.
Presentation to the specialists of the treatment preferences of their colleagues did not appear to change their decisions about treatment. There was, however, a marked increase in the number of physicians who chose treatment that included chemotherapy for locally advanced bladder cancer. There was an 18 month interval between the two questionnaires. Chemotherapy is being used increasingly in this clinical setting but we are not aware of any definitive evidence to support the use of chemotherapy for locally advanced bladder cancer that has been published between the times of the two questionnaires. While the use of chemotherapy may be logical in a disease with a poor prognosis and a high rate of metastatic failure, it remains experimental therapy. Many respondents may have preferred to be treated with experimental therapy, rather than with an established standard treatment that is known to offer a low probability of cure.
The high rate of return seen in both our original and follow-up surveys indicates that physicians are supportive of such endeavours and that the information obtained is representative of the opinions of the expert community. It also suggests that this method could be applied more generally as an aid in clinical investigation. We believe that surveys such as ours provide information useful for both patient management and clinical trials. They can define current treatment policies and controversies and can frame meaningful questions which could be addressed in clinical trials. Knowledge about the acceptability of clinical trials to expert physicians furnishes useful information as to whether these trials address relevant issues, can identify potential problems in their execution and can identify trials that offer unconventional treatment. We also believe that this method can strengthen the ethical validity of a proposed trial.
Patients traditionally rely on their individual physician for guidance as to whether they should consent to be randomised in a trial, and it has been demonstrated that the opinions of expert physicians influence the decisions of lay people to take part in clinical trials (Mackillop et al., 1989) . The demonstration that a clinical trial seeks to answer a question about which controversy exists among experts, and that all proposed treatment options are acceptable within the expert community, is information that both patients and institutional review boards would find pertinent.
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